Want to see ALLR full AI Analyst Report?
ALLR Stock Chart & Stats
$1.34
$0.04(3.36%)
At close: 4:00 PM EDT
$1.34
$0.04(3.36%)
Day’s Range― - ―
52-Week Range$0.77 - $1.84
Previous Close$1.21
Volume25.03K
Average Volume (3M)117.88K
Market Cap
$13.25M
Enterprise Value$15.83M
Total Cash (Recent Filing)$16.98M
Total Debt (Recent Filing)$22.29M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Nov 12, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding15,910,724
10 Day Avg. Volume102,110
30 Day Avg. Volume117,875
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.58
Price to Sales (P/S)48.53
P/FCF Ratio-1.05
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue45.88
Enterprise Value/Gross Profit42.67
Enterprise Value/Ebitda-1.43
Forecast
1Y Price Target
$11.00Price Target Upside720.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.92
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Personalized Oncology PlatformDRP® gives Allarity a differentiated, biomarker-led approach to patient selection in oncology. If validated clinically, this platform could improve response rates, sharpen trial design, and make development resources more efficient across the company’s drug pipeline.
Oncology Pipeline BreadthMultiple oncology programs and indications provide more than one potential path to clinical value creation. A broader pipeline can diversify development outcomes and allow the DRP® platform to be applied across cancers where patient selection may improve therapeutic results.
Improving Loss ProfileLosses have materially improved from 2024 levels, indicating some reduction in the earnings deficit even though the company remains far from breakeven. Continued operating discipline could extend its development runway and reduce the pace at which additional capital is required.
Bears Say
Minimal Revenue And No GrowthThe company currently generates only minimal revenue and has no reported growth trend, leaving its economics dependent on future clinical and commercial milestones. This weak revenue base limits internal funding capacity and makes sustainable profitability difficult to establish over the next several quarters.
Persistent Cash BurnOngoing operating and free-cash-flow losses show that the business is consuming substantial cash rather than funding itself. Because burn is not consistently declining, Allarity may need continued external financing to sustain clinical development and other operations.
Highly Leveraged Balance SheetDebt substantially exceeds equity, creating a structurally weak capital position for a loss-making clinical-stage company. Elevated leverage increases refinancing pressure and may force dilution or other financing actions, potentially limiting strategic flexibility while development spending continues.
Allarity Therapeutics News
ALLR FAQ
What was Allarity Therapeutics, Inc.’s price range in the past 12 months?
Allarity Therapeutics, Inc. lowest stock price was $0.77 and its highest was $1.84 in the past 12 months.
What is Allarity Therapeutics, Inc.’s market cap?
Allarity Therapeutics, Inc.’s market cap is $13.25M.
When is Allarity Therapeutics, Inc.’s upcoming earnings report date?
Allarity Therapeutics, Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 25 days.
How were Allarity Therapeutics, Inc.’s earnings last quarter?
Allarity Therapeutics, Inc. released its earnings results on Aug 14, 2026. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.04.
Is Allarity Therapeutics, Inc. overvalued?
According to Wall Street analysts Allarity Therapeutics, Inc.’s price is currently Undervalued.
Does Allarity Therapeutics, Inc. pay dividends?
Allarity Therapeutics, Inc. does not currently pay dividends.
What is Allarity Therapeutics, Inc.’s EPS estimate?
Allarity Therapeutics, Inc.’s EPS estimate is -0.21.
How many shares outstanding does Allarity Therapeutics, Inc. have?
Allarity Therapeutics, Inc. has 15,910,724 shares outstanding.
What happened to Allarity Therapeutics, Inc.’s price movement after its last earnings report?
Allarity Therapeutics, Inc. reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went up 0.735%.
Which hedge fund is a major shareholder of Allarity Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ALLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
ALLR Stock 12 Month Forecast
Average Price Target
$11.00
▲(720.90% Upside)
Technical Analysis
Ownership Overview
7.69% Insiders
1.90% Mutual Funds
0.62% Other Institutional Investors
88.71% Public Companies and
Individual Investors